HLS- A Phase 1 Open-Label Dose-Escalation with Expansion Study of SX-682 in MDS Patients
HLS-SX-682 在 MDS 患者中的 1 期开放标签剂量递增和扩展研究
基本信息
- 批准号:9789451
- 负责人:
- 金额:$ 142.44万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-01 至 2021-08-31
- 项目状态:已结题
- 来源:
- 关键词:Acute Myelocytic LeukemiaAffectB-LymphocytesBiological MarkersBone MarrowBusinessesCellsClinicClinicalClinical DataCodeCooperative Research and Development AgreementCyclic GMPData AnalyticsDependenceDiseaseDisease remissionDoseDose-LimitingDysmyelopoietic SyndromesEnrollmentEvaluationExhibitsFDA approvedFailureFormulationFundingGoalsGrowthHematological DiseaseHematologyHematopoieticHematopoietic NeoplasmsHematopoietic stem cellsIL8 geneIL8RA geneIL8RB geneImmunologic SurveillanceImmunooncologyImmunosuppressive AgentsImmunotherapeutic agentImpairmentLeadLifeLigandsMarrowMeasuresMetastatic MelanomaMorphologyMyeloid-derived suppressor cellsNational Heart, Lung, and Blood InstituteNatural Killer CellsNon-MalignantOralPatientsPharmaceutical PreparationsPhasePhase I Clinical TrialsPrior TherapyProtocols documentationRecordsRefractoryRegulatory T-LymphocyteRelapseRiskSafetySeveritiesSignal TransductionSiteSmall Business Innovation Research GrantSomatic MutationStem cellsSymptomsSyndromeT-LymphocyteTestingTherapeuticTimeToxic effectTransfusionUnited StatesWorkacute myeloid leukemia cellbaseblood productcell growthchemokinecohortcostcytopeniagene therapygranulocyte-monocyte progenitorshigh riskimmune clearanceinterestmelanomamutantneutrophilnovelnovel therapeuticsopen labeloutcome forecastoverexpressionpre-clinicalprogenitorreceptorrecruitresearch clinical testingresponseside effectsmall moleculestandard of carestemtherapeutic target
项目摘要
This SBIR Fast-Track proposal meets the objectives of NHLBI Small Business Topic of Special Interest for
Fiscal Year 2017 Code HLS17-04. Myelodysplastic syndromes (MDS) are genetically and morphologically
diverse hematopoietic neoplasms that arise from a small pool of mutant clones within hematopoietic stem and
progenitor compartments. Only three drugs have received regulatory approval specifically for MDS treatment,
all with suboptimal response rates of <50% and of limited durability, typically 1-2 years. Once these agents are
no longer effective, there is no standard of care established for second-line treatment (i.e., in the
relapsed/refractory setting). Furthermore, prognosis after hypomethylating agent failure is dismal, with median
survival estimated at <6 months for higher-risk patients, and <18 months for lower-risk patients. Clearly there
is a significant unmet need for a new MDS treatment that both (a) eradicates preleukemic stem cells and leads
to long-term remission and normalization of cytopenias, and (b) achieves this goal without the heavy cost of
side effects, particularly in lower-risk MDS.
Stem cells and early progenitors from MDS patients consistently overexpressed the chemokine CXCL8
(IL-8) and its receptor, CXCR2. Inhibition of CXCR2 selectively arrested the growth of stem cells from MDS
patients but not healthy controls, demonstrating preclinical therapeutic proof-of-principle and validating CXCR2
as a therapeutic target in MDS. Additionally, myeloid-derived suppressor cells (MDSCs) are markedly
increased in the bone marrow of MDS patients where they induce myelodysplasia and impair immune
surveillance and clearance of mutant clones. CXCR2 and CXCR1 are pivotal in MDSC recruitment. Dual
CXCR1 and CXCR2 (CXCR1/2) inhibition is therefore a novel therapeutic strategy to treat MDS with a “one-
two punch” to (i) the mutant MDS cells directly and (ii) the MDSC-driven immunosuppressive marrow
microenvironment.
Developed by Syntrix in a decade's long discovery effort supported by NHLBI (IND open for melanoma
4/16), SX-682 is a new-in-class oral, small-molecule, immuno-oncology (IO) therapy directed at disrupting
CXCR1/2 signaling. We hypothesize that in MDS, SX-682 will lead to long-term remissions and normalization
of cytopenias, but with only a mild side-effect effect profile compared to other therapies. If successful, SX-682
would revolutionize the existing treatment landscape in MDS. Through execution of the Specific Aims, we will
advance SX-682 through a Phase 1, open label dose-escalation and expansion trial to evaluate SX-682 in
MDS patients who had progression or were intolerant to prior therapy. The SX-682 MDS IND 131,876 was
opened on September 1, 2017, and enrollment for this trial may begin.
此SBIR快速通道提案符合NHLBI小型企业特别关注主题的目标,
2017财年代码HLS 17 -04。骨髓增生异常综合征(MDS)是遗传和形态学
由造血干细胞内的一小部分突变克隆引起的多种造血肿瘤,
祖细胞室只有三种药物获得了专门用于MDS治疗的监管批准,
所有这些都具有<50%的次优响应率和有限的耐久性,通常为1-2年。一旦这些特工
不再有效,没有建立用于二线治疗的护理标准(即,在
复发/难治性环境)。此外,低甲基化剂失败后的预后令人沮丧,
高风险患者估计生存期<6个月,低风险患者估计生存期<18个月。颇为明显的一点
是对新的MDS治疗的显著未满足的需求,所述新的MDS治疗(a)根除白血病前干细胞并导致
血细胞减少症的长期缓解和正常化,以及(B)实现该目标而不需要以下的沉重代价:
副作用,特别是在低风险MDS中。
MDS患者的干细胞和早期祖细胞持续过表达趋化因子CXCL 8
(IL-8)及其受体CXCR 2。抑制CXCR 2选择性抑制MDS干细胞生长
患者而非健康对照,证明了临床前治疗原理验证并验证了CXCR 2
作为MDS的治疗靶点。此外,髓源性抑制细胞(MDSC)明显
在MDS患者的骨髓中增加,在那里它们诱导骨髓发育不良并损害免疫功能
监测和清除突变克隆。CXCR 2和CXCR 1在MDSC招募中起关键作用。双
因此,CXCR 1和CXCR 2(CXCR 1/2)抑制是一种用“一个-
(i)突变型MDS细胞直接和(ii)MDSC驱动的免疫抑制骨髓
微环境
由Syndrome在NHLBI(IND开放用于黑色素瘤)的支持下,经过十年的长期发现努力开发
4/16),SX-682是一种新型口服小分子免疫肿瘤学(IO)疗法,旨在破坏
CXCR 1/2信号传导。我们假设,在MDS中,SX-682将导致长期缓解和正常化
血细胞减少症,但与其他疗法相比,只有轻微的副作用。如果成功,SX-682
将彻底改变MDS的现有治疗格局。通过执行具体目标,我们将
通过1期、开放标签剂量递增和扩展试验推进SX-682,以评估SX-682在
发生进展或对既往治疗不耐受的MDS患者。SX-682 MDS IND 131,876是
于2017年9月1日开放,本试验的入组可能开始。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STUART J KAHN其他文献
STUART J KAHN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STUART J KAHN', 18)}}的其他基金
A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects
一项 1 期随机单次口服剂量四期交叉研究,调查 Omnitram 剂量比例和食物对正常人类受试者的影响
- 批准号:
10372803 - 财政年份:2019
- 资助金额:
$ 142.44万 - 项目类别:
A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects
一项 1 期随机单次口服剂量四期交叉研究,调查 Omnitram 剂量比例和食物对正常人类受试者的影响
- 批准号:
10029002 - 财政年份:2019
- 资助金额:
$ 142.44万 - 项目类别:
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma
评估新型小分子免疫肿瘤拮抗剂 SX-682 单独使用以及与 Pembrolizumab 联合治疗转移性黑色素瘤的 1 期临床试验
- 批准号:
9348033 - 财政年份:2017
- 资助金额:
$ 142.44万 - 项目类别:
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma
评估新型小分子免疫肿瘤拮抗剂 SX-682 单独使用以及与 Pembrolizumab 联合治疗转移性黑色素瘤的 1 期临床试验
- 批准号:
10189528 - 财政年份:2017
- 资助金额:
$ 142.44万 - 项目类别:
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma
评估新型小分子免疫肿瘤拮抗剂 SX-682 单独使用以及与 Pembrolizumab 联合治疗转移性黑色素瘤的 1 期临床试验
- 批准号:
9755385 - 财政年份:2017
- 资助金额:
$ 142.44万 - 项目类别:
Phase II clinical evaluation of Omnitram in neuropathic pain
Omnitram 治疗神经病理性疼痛的 II 期临床评价
- 批准号:
8981655 - 财政年份:2015
- 资助金额:
$ 142.44万 - 项目类别:
Phase II clinical evaluation of Omnitram in neuropathic pain
Omnitram 治疗神经病理性疼痛的 II 期临床评价
- 批准号:
9317459 - 财政年份:2015
- 资助金额:
$ 142.44万 - 项目类别:
Efficacy and resistance mechanisms of LD-aminopterin in psoriasis
LD-氨基蝶呤治疗银屑病的疗效及耐药机制
- 批准号:
8792437 - 财政年份:2014
- 资助金额:
$ 142.44万 - 项目类别:
Efficacy and resistance mechanisms of LD-aminopterin in psoriasis
LD-氨基蝶呤治疗银屑病的疗效及耐药机制
- 批准号:
9188625 - 财政年份:2014
- 资助金额:
$ 142.44万 - 项目类别:
Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers
克服 CYP2D6 代谢不良者的曲马多耐药性
- 批准号:
8713969 - 财政年份:2010
- 资助金额:
$ 142.44万 - 项目类别:
相似海外基金
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 142.44万 - 项目类别:
Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 142.44万 - 项目类别:
Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 142.44万 - 项目类别:
Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 142.44万 - 项目类别:
Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 142.44万 - 项目类别:
Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 142.44万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 142.44万 - 项目类别:
Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 142.44万 - 项目类别:
Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
- 批准号:
23K00129 - 财政年份:2023
- 资助金额:
$ 142.44万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
- 批准号:
2883985 - 财政年份:2023
- 资助金额:
$ 142.44万 - 项目类别:
Studentship